Theriva Biologics Files 8-K on Financials
Ticker: TOVX · Form: 8-K · Filed: Mar 25, 2024 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, filing
TL;DR
Theriva Biologics dropped an 8-K on March 25th detailing their financial condition and operations.
AI Summary
On March 25, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. Theriva Biologics, formerly known as Synthetic Biologics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides investors with crucial updates on Theriva Biologics' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- March 25, 2024 (date) — Filing date
- Synthetic Biologics, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this 8-K filing for Theriva Biologics, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 25, 2024.
What was Theriva Biologics, Inc. previously named?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc.
In which U.S. state is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the Standard Industrial Classification code for Theriva Biologics, Inc.?
The Standard Industrial Classification code for Theriva Biologics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-03-25 07:40:33
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm249466d1_8k.htm (8-K) — 27KB
- tm249466d1_ex99-1.htm (EX-99.1) — 92KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 4KB
- image_003.jpg (GRAPHIC) — 4KB
- image_004.jpg (GRAPHIC) — 4KB
- image_005.jpg (GRAPHIC) — 4KB
- image_006.jpg (GRAPHIC) — 4KB
- 0001104659-24-038166.txt ( ) — 334KB
- syn-20240325.xsd (EX-101.SCH) — 3KB
- syn-20240325_lab.xml (EX-101.LAB) — 33KB
- syn-20240325_pre.xml (EX-101.PRE) — 22KB
- tm249466d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On March 25, 2024, Theriva Biologics, Inc., a Nevada corporation (the "Registrant") issued a press release that included financial information for its fiscal year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated March 25, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 25, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer